Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

U.S. CDC advisers mull COVID-19 boosters for immune-compromised people

Published 07/22/2021, 12:47 PM
Updated 07/22/2021, 04:16 PM
© Reuters. FILE PHOTO: A general view of the U.S. Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014.  REUTERS/Tami Chappell

By Julie Steenhuysen

CHICAGO (Reuters) -Advisers to the U.S. Centers for Disease Control and Prevention on Thursday will consider evidence suggesting that a booster dose of COVID-19 vaccines could increase protection among people with compromised immune systems.

Data presented ahead of the meeting noted that such people have a reduced antibody response following the recommended primary vaccination series compared with healthy individuals.

"Emerging data suggest that an additional COVID-19 vaccine dose in immunocompromised people enhances antibody response and increases the proportion who respond," slides released ahead of the meeting showed.

The committee is not scheduled to vote on a recommendation for whether to administer additional doses. That could be decided at a later meeting.

In small studies, short-term side effects from a third dose of mRNA vaccines - such as those made by BioNTech/Pfizer Inc or Moderna (NASDAQ:MRNA) Inc - were about the same as those experienced with the first two doses, the CDC said in its presentation.

An estimated 2.7% of U.S. adults live with weakened immune systems, according to the CDC presentation, based on data from 2013. The group includes people living with HIV/AIDS, cancer and people with organ transplants or autoimmune diseases who take drugs to dampen their immune response.

Those individuals are at increased risk of severe disease and death from COVID-19.

Last week, Israel began administering third doses of the Pfizer/BioNTech vaccine to immunocompromised people, including those who have had heart, lung, kidney or liver transplants and cancer patients receiving chemotherapy.

Some experts believe the CDC is nearing a similar recommendation in the United States.

© Reuters. FILE PHOTO: A healthcare worker administers a shot of the Moderna COVID-19 Vaccine to a woman at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in Manhattan in New York City, New York, U.S., January 29, 2021. REUTERS/Mike Segar

The CDC has urged people with weakened immune systems to take precautions even if fully vaccinated against COVID-19.

The virus not only poses an extra health risk to these people but because it takes longer for them to clear the virus, scientists believe infections could result in new variants as the pathogen continues to replicate unchecked, which some studies have shown.

Latest comments

So technically 2.7% of the population needs the shot while the rest will naturally build immunity to it, just like most other viruses. Glad usa spent $30 Billion on this stuff. Aka: pharma payday
One more shots after 2 shots its the way its go….
What happened to herd immunity or does that get in the way of Pfizer business plan?
Half the herd wants to follow the lead conspiracy 🦬 buffalo and jump over the cliff. This is known as herd mentality.
3 Pfizer shots now?
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.